ArticleFrontiers in aging2026
Rumo zhentong Yin for blood-stasis-type osteoporotic pain: protocol of a randomized, single-blind, controlled trial.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoporosis (OP) is a metabolic skeletal disease characterized by reduced bone mass and micro-architectural deterioration, with Osteoporotic pain (OPP) as its most common clinical symptom, which markedly impairs quality of life. Modern pharmacologic treatments' limitations are obvious with population aging, so the cost-effective interventions for OPP are urgently needed. As an empirical formula, Rumo zhentong Yin has been created by the national renowned veteran Traditional Chinese Medicine (TCM) practitioner Yao Shujin for blood-stasis pain. Hence, this trial was designed to investigate the efficacy of Rumo zhentong Yin in treating blood-stasis-type OPP. Methods: A randomized, single-blind, controlled trial was designed to evaluate the efficacy of Rumo zhentong Yin combined with standard therapy for OPP. Eligible OPP patients were recruited and randomly assigned (1:1) to form either the control or treatment group. Both groups received standard treatment. The intervention lasted 3 months, with follow-up evaluations every 4 weeks. Primary outcome was pain scores; secondary outcomes included bone mineral density (BMD), bone-turnover markers, inflammatory cytokines, blood-stasis syndrome score and hematological indices. Anticipated Results: To our knowledge, this trial is the first clinical study of Rumo zhentong Yin for OPP, with the primary objective to provide robust clinical evidence supporting the integration of Traditional Chinese and Western medicine for OPP. Trial Registration: The trial was registered at the International Traditional Medicine Clinical Trial Registry (www.itmctr.ccebtcm.org.cn) on 2026-01-08 (ITMCTR2026000740).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.